Advanced

Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease.

Lundin, Anders LU ; Dietrichs, Espen; Haghighi, Sara; Göller, Marie-Louise; Heiberg, Arvid; Loutfi, Ghada; Widner, Håkan LU ; Wiktorin, Klas; Wiklund, Leif and Svenningsson, Anders, et al. (2010) In Clinical neuropharmacology 33. p.260-264
Abstract
OBJECTIVES:: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease (HD). METHODS:: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, assessed by cognitive tests (Symbol Digit Modalities, verbal fluency, and Stroop tests). Secondary outcome measures included changes in the Unified Huntington's Disease Rating Scale, Hospital Anxiety and Depression Scale, Leeds Sleep Evaluation Questionnaire, Reitan Trail-Making Test A, and Clinical Global Impression of Change. Safety assessments were also... (More)
OBJECTIVES:: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease (HD). METHODS:: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, assessed by cognitive tests (Symbol Digit Modalities, verbal fluency, and Stroop tests). Secondary outcome measures included changes in the Unified Huntington's Disease Rating Scale, Hospital Anxiety and Depression Scale, Leeds Sleep Evaluation Questionnaire, Reitan Trail-Making Test A, and Clinical Global Impression of Change. Safety assessments were also performed. RESULTS:: There was no significant difference between pridopidine and placebo in the change from baseline of the weighted cognitive score. However, secondary measures such as affective symptoms showed trends toward improvement, and there was significant improvement in voluntary motor symptoms compared with placebo (P < 0.05). Pridopidine was well tolerated, with a safety profile similar to placebo. CONCLUSIONS:: Pridopidine shows promise as a treatment for some of the symptoms of HD. In this small-scale study, the most notable effect was improvement in voluntary motor symptoms. Larger, longer-term trials are warranted. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical neuropharmacology
volume
33
pages
260 - 264
external identifiers
  • wos:000282134400011
  • pmid:20616707
  • scopus:77957986360
ISSN
1537-162X
DOI
10.1097/WNF.0b013e3181ebb285
language
English
LU publication?
yes
id
67bb8417-d781-4a79-87b3-acd6d71cf0ed (old id 1645157)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20616707?dopt=Abstract
date added to LUP
2010-08-02 11:34:35
date last changed
2017-04-09 04:35:59
@article{67bb8417-d781-4a79-87b3-acd6d71cf0ed,
  abstract     = {OBJECTIVES:: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease (HD). METHODS:: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, assessed by cognitive tests (Symbol Digit Modalities, verbal fluency, and Stroop tests). Secondary outcome measures included changes in the Unified Huntington's Disease Rating Scale, Hospital Anxiety and Depression Scale, Leeds Sleep Evaluation Questionnaire, Reitan Trail-Making Test A, and Clinical Global Impression of Change. Safety assessments were also performed. RESULTS:: There was no significant difference between pridopidine and placebo in the change from baseline of the weighted cognitive score. However, secondary measures such as affective symptoms showed trends toward improvement, and there was significant improvement in voluntary motor symptoms compared with placebo (P &lt; 0.05). Pridopidine was well tolerated, with a safety profile similar to placebo. CONCLUSIONS:: Pridopidine shows promise as a treatment for some of the symptoms of HD. In this small-scale study, the most notable effect was improvement in voluntary motor symptoms. Larger, longer-term trials are warranted.},
  author       = {Lundin, Anders and Dietrichs, Espen and Haghighi, Sara and Göller, Marie-Louise and Heiberg, Arvid and Loutfi, Ghada and Widner, Håkan and Wiktorin, Klas and Wiklund, Leif and Svenningsson, Anders and Sonesson, Clas and Waters, Nicholas and Waters, Susanna and Tedroff, Joakim},
  issn         = {1537-162X},
  language     = {eng},
  pages        = {260--264},
  series       = {Clinical neuropharmacology},
  title        = {Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease.},
  url          = {http://dx.doi.org/10.1097/WNF.0b013e3181ebb285},
  volume       = {33},
  year         = {2010},
}